CGIX - Cancer Genetics more than doubles after merger terms update

Nano cap contract research firm Cancer Genetics ([[CGIX]] +106.3%) has more than doubled in value today following two consecutive days of gains each topping 20%.Earlier in the week, the company filed a Form 8-K with SEC detailing the amendments to its proposed merger agreement with StemoniX, Inc.The shareholders of Cancer Genetics will be asked to vote on the merger and proposal for a reverse stock split in the range of one for two shares to one for 10 shares.Additionally, an existing investor of StemoniX is expected to purchase an additional $3 million of StemoniX convertible notes.In August, Cancer Genetics more than tripled in value on the announcement of its merger agreement with privately-held StemoniX.

For further details see:

Cancer Genetics more than doubles after merger terms update